Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carlo Perricone, Elena Bartoloni, Roberto Gerli
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2020
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05c69d9bf924417f96de790ea9f6910c
record_format	dspace
spelling	oai:doaj.org-article:05c69d9bf924417f96de790ea9f6910c2021-12-02T17:18:53ZColchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-190034-62332084-983410.5114/reum.2020.100088https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c2020-10-01T00:00:00Zhttps://www.termedia.pl/Colchicine-an-anti-rheumatic-agent-as-a-potential-compound-for-the-treatment-of-COVID-19,18,42137,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, a -coronavirus which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome [1].Carlo PerriconeElena BartoloniRoberto GerliTermedia Publishing HousearticleMedicineRENRheumatology, Vol 58, Iss 5, Pp 261-264 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Carlo Perricone Elena Bartoloni Roberto Gerli Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
description	The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, a -coronavirus which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome [1].
format	article
author	Carlo Perricone Elena Bartoloni Roberto Gerli
author_facet	Carlo Perricone Elena Bartoloni Roberto Gerli
author_sort	Carlo Perricone
title	Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_short	Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_full	Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_fullStr	Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_full_unstemmed	Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_sort	colchicine, an anti-rheumatic agent, as a potential compound for the treatment of covid-19
publisher	Termedia Publishing House
publishDate	2020
url	https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c
work_keys_str_mv	AT carloperricone colchicineanantirheumaticagentasapotentialcompoundforthetreatmentofcovid19 AT elenabartoloni colchicineanantirheumaticagentasapotentialcompoundforthetreatmentofcovid19 AT robertogerli colchicineanantirheumaticagentasapotentialcompoundforthetreatmentofcovid19
_version_	1718381064470134784

Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19

Ejemplares similares